RESEARCH STUDY ANNOUNCEMENT

The purpose of this research study is to investigate the effect of interferon-γ (IFN-γ) on white blood cell function in patients with Chronic Granulomatous Disease (CGD).

Who is eligible to participate?

- Patients with all genetic types of CGD
- Males and females 5-60 years of age are eligible
- Patients should be free from acute infections and chronic medical problems
- Taking prophylactic antibiotics and antifungal medication

What are the main procedures involved?

➢ If you are a patient outside of Colorado and you are currently taking IFN-γ:
  - You will stop taking IFN-γ for a period of one week.
  - You will travel to Children's Hospital Colorado for all your study visits. You will have blood drawn for research a total of three times over a period of 9 days.
  - You will resume treatment with IFN-γ three times a week, on Monday, Wednesday, and Friday.
  - Patients take their own medication.

➢ If you are a patient outside of Colorado and you are not currently taking IFN-γ:
  - You will travel to Children's Hospital Colorado for all your study visits. You will have blood drawn for research a total of three times over a period of 9 days.
  - You will begin treatment with IFN-γ three times a week, on Monday, Wednesday, and Friday.
  - Patients take their own medication.

Blood collected for this study is used for genetic analysis and cell function studies.

If you must travel more than 50 miles to participate in the study, the cost of your travel will be covered. Study staff will work with you to make travel arrangements.

Compensation is provided for completion of the protocol.

Study Sponsor: Horizon Pharma Ireland LTD.

For more information, contact the PI, Daniel R. Ambruso, MD. 303-324-2171 or Daniel.ambruso@ucdenver.edu